רווח תפעולי לפני פחת: tarsusrx.com (TARS)

Tarsus Pharmaceuticals (TARS) is attracting leading biotech specialists to develop unique ophthalmological treatments. EBITDA cash flow confirms the effectiveness of this strategy, where the current status is 0.00. Business development relies on partnerships with medical centers for distribution. Meanwhile, management is successfully transforming the company from a research-and-development structure into a commercial enterprise with high investor confidence.

Outsourcing the production of ophthalmological drugs to contract organizations makes Tarsus Pharmaceuticals (TARS) dependent on external logistics and the stability of CMOs. By analyzing the absolute cash result of operations, an investor assesses the real cash flow from core activities, which allows for measuring the business's speed of adaptation to stress and determining the actual capital cushion amid market volatility.